Literature DB >> 10819155

Adherence and drug resistance: predictions for therapy outcome.

L M Wahl1, M A Nowak.   

Abstract

We combine standard pharmacokinetics with an established model of viral replication to predict the outcome of therapy as a function of adherence to the drug regimen. We consider two types of treatment failure: failure to eliminate the wild-type virus, and the emergence of drug-resistant virus. Specifically, we determine the conditions under which resistance dominates as a result of imperfect adherence. We derive this result for both single- and triple-drug therapies, with attention to conditions which favour the emergence of viral strains that are resistant to one or more drugs in a cocktail. Our analysis provides quantitative estimates of the degree of adherence necessary to prevent resistance. We derive results specific to the treatment of human immunodeficiency virus infection, but emphasize that our method is applicable to a range of viral or other infections treated by chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10819155      PMCID: PMC1690604          DOI: 10.1098/rspb.2000.1079

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  38 in total

Review 1.  Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV.

Authors:  A R McLean; M A Nowak
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

Review 2.  Disease transmission dynamics and the evolution of antibiotic resistance in hospitals and communal settings.

Authors:  S A Levin; a V Andreasen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

Review 3.  Seasonality and the requirements for perpetuation and eradication of viruses in populations.

Authors:  J A Yorke; N Nathanson; G Pianigiani; J Martin
Journal:  Am J Epidemiol       Date:  1979-02       Impact factor: 4.897

4.  Antigenic diversity thresholds and the development of AIDS.

Authors:  M A Nowak; R M Anderson; A R McLean; T F Wolfs; J Goudsmit; R M May
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

5.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

Review 6.  Compliance in clinical trials.

Authors:  C L Besch
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

7.  Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.

Authors:  S D Frost; A R McLean
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

8.  The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics.

Authors:  D J Austin; N J White; R M Anderson
Journal:  J Theor Biol       Date:  1998-10-07       Impact factor: 2.691

9.  Population biology of infectious diseases: Part II.

Authors:  R M May; R M Anderson
Journal:  Nature       Date:  1979-08-09       Impact factor: 49.962

10.  Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.

Authors:  D D Richman; T C Meng; S A Spector; M A Fischl; L Resnick; S Lai
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-02
View more
  38 in total

1.  HIV therapy: managing resistance.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 2.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.

Authors:  Dominique Cadosch; Sebastian Bonhoeffer; Roger Kouyos
Journal:  J R Soc Interface       Date:  2012-03-14       Impact factor: 4.118

4.  Costs versus benefits: best possible and best practical treatment regimens for HIV.

Authors:  O Krakovska; L M Wahl
Journal:  J Math Biol       Date:  2007-01-05       Impact factor: 2.259

5.  Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.

Authors:  Libin Rong; Michael A Gilchrist; Zhilan Feng; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-04-19       Impact factor: 2.691

6.  Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?

Authors:  R J Smith
Journal:  Proc Biol Sci       Date:  2006-03-07       Impact factor: 5.349

7.  A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

8.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-03-04       Impact factor: 2.745

9.  Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.

Authors:  Romulus Breban; Sonia Napravnik; James Kahn; Sally Blower
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

10.  Reconciling conflicting clinical studies of antioxidant supplementation as HIV therapy: a mathematical approach.

Authors:  Rolina D van Gaalen; Lindi M Wahl
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.